Imaging response in malignant glioma, RTOG 90-06

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 1, 2007, Pages 32-37

  Lustig, Robert A ^a   Seiferheld, Wendy ^b   Berkey, Brian ^b   Yung, Alfred W K ^c   Scarantino, Charles ^d   Movsas, Benjamin ^e   Jones, Christopher U ^f   Simpson, Joseph R ^g   Fishbach, Jennifer ^h   Curran Jr , Walter J ⁱ  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b RTOG Headquarters   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Rex Hospital   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f Sutter Medical Center   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h LDS HOSPITAL   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Imaging response; Malignant glioma; Radiation therapy

Indexed keywords

CARMUSTINE;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HISTOLOGY; HUMAN; IMAGING SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; RADIODIAGNOSIS; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BIOPSY; BRAIN NEOPLASMS; CARMUSTINE; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33846809071     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000236214.13206.38     Document Type: Article

References (12)

1. Seiferheld W, Mehta M, DelRowe J, et al. Five years of glioblastoma multiforme (GBM) phase II trials at the Radiation Therapy Oncology Group (RTOG). Proceeding from Am Soc Clin Oncol (ASCO), Orlando, FL. J Clin Oncol. 1997:pg 71, Abstract 283.
2. CBTRUS. (1992-1997) Statistical Report: Primary Brain Tumors in the United States. Published by the Central Brain Tumor Registry of the United States, 2000:24-25.
3. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three radiation oncology group malignant glioma trials. J Natl Cancer Inst. 1993;85:704-710.
4. Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys. 1998;40:51-55.
5. Curran W, Scott C, Yung W, et al. No survival benefit of hyperfractionated radiotherapy (RT) to 72.0 Gy & carmustine versus standard RT & carmustine for malignant glioma patients: preliminary results of RTOG 90-06. Proceedings of the American Society of Clinical Oncology (ASCO), Philadelphia, PA. Am Soc Clin Oncol. 1996:154. Abstract.
6. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations J Am Stat Assoc. 1958;53:457-481.
7. Prentice RL, Marek P. A qualitative discrepancy between censored data rank tests. Biometrics. 1979;35:861-867.
8. Cox DR. Regression models and life-tables. JR Stat Soc. [Br]. 1972;34:187-220.
9. Enzman ND, Levin VA, Wilson CB, et al. Computed tomography in the evaluation of malignant glioma before and after therapy. Radiology. 1976;121:85-88.
10. Marks JE, Gado M. Serial computed tomography of primary brain tumors following surgery, irradiation and chemotherapy. Radiology. 1977;125:119-125.
11. Levin VA, Hoffman WF, Heilbron DC, et al. Prognostic significance of the pretreatment CT scan on time to progression for patients with malignant gliomas. J Neurosurg. 1980;52:642-647.
12. Gasper LE, Fisher BJ, MacDonald DR, et al. Malignant glioma-timing of response to radiation therapy. Int J Radiat Oncol Biol Phys. 1993;5:877-880.